Jun 07, 2019 / 02:30PM GMT
Maurice Thomas Raycroft - Jefferies LLC, Research Division - Equity Analyst
Hi. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. It's with great pleasure that I'd like to introduce Barry Greene, the President at Alnylam; and Manmeet Soni, the CFO at Alnylam. Thanks so much for joining us today. We're going to have a fireside chat, so pretty informal conversation.
Barry E. Greene - Alnylam Pharmaceuticals, Inc. - President
Sounds good.
Questions and Answers:
Maurice Thomas Raycroft - Jefferies LLC, Research Division - Equity AnalystMaybe if you just want to give us an intro to Alnylam and give us an update on the company.
Barry E. Greene - Alnylam Pharmaceuticals, Inc. - President
So how long do we have? Maury, thank you for having us and thanks to the organizers for having us as well. It's really a pleasure to be here.
Alnylam is the leading RNAi therapeutic company, and the company is about 17 years old. And we started Alnylam
Trustpilot
